J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
BHP Shares Fall as Jansen Potash Project Costs Surge 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
TUCSON, Ariz., Jan. 27, 2016 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 in New York.
HTG management is scheduled to present at 8:25 a.m. ET. A live audio webcast of the presentation can be accessed by visiting the “Investors” section of HTG’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG Molecular Diagnostics:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
